Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
about
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaAppraisal of immunoglobulin free light chain as a marker of responseReview of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patientsImmunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature.Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.Association between abnormal serum free light chains ratio and known prognostic factors in lymphoma; a nephrology viewpoint.Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomicsFree immunoglobulin light chain (FLC) promotes murine colitis and colitis-associated colon carcinogenesis by activating the inflammasome.Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.The evolving use of serum free light chain assays in haematology.Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaSerum free light chains and the risk of ESRD and death in CKDDirect tissue evaluation via immunofluorescence: in the diagnosis of hereditary transthyretin cardiac amyloidosis.Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myelomaUtility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.Genetic events in the pathogenesis of multiple myeloma.Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myelomaElevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.Clinical challenges of an oligosecretory plasma cell dyscrasia.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation.Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisScreening panels for detection of monoclonal gammopathies.Association between free light chain levels, and disease progression and mortality in chronic kidney disease.Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias.Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review.Multiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient.The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease.Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies.Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions.Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients.
P2860
Q24619589-F47AE94A-E8DC-4F9C-A0D8-353D379B8535Q24624398-545FB42D-38DF-4AC6-BA64-4180AA2DD0BFQ28291793-487399F8-462F-4DDE-B3DE-125CF609ECB6Q31146661-CE3BF48C-38F9-4D99-A79E-87ADB6F423D7Q33371085-9B570220-85C6-48C2-BA37-A3B53E8463C5Q33652326-D10C531D-0A68-49E9-9095-48C6C48170C1Q33828590-F37739BD-110F-4F63-BC15-A2DE7E4D40F4Q33899492-77241367-ABB9-4F45-9034-0682E0D2E436Q34091229-DF40A552-5D15-4B01-AA9C-BF94C363BE42Q34450428-38A3C656-3BBB-4FD4-9E8C-46654377AF3FQ34758218-60167D8C-1EC5-4A7D-BF3E-0ABDEAE4B9F1Q34866311-8606F229-E14E-4C7C-BA80-6F4F19FEC3ADQ34882773-5D387F3F-44B1-4730-B7DE-A793928460CFQ35185207-39CF8063-735A-43C9-86AD-8A6CFC45C731Q35664565-0A8A8997-CEEB-4E5C-9571-140DA6A1E25EQ35820083-43A905B7-1486-41DC-8DB9-704F29F8BD29Q36033380-9EF4E848-151A-4406-836D-4AD3727F38A6Q36137449-8BBF0148-D45D-4C18-8B4D-79DA48079144Q36380235-FBA79BE2-7A71-4CA9-A850-18BC39B001BBQ36572310-73B449D1-85D5-41F3-A60E-7A376150019EQ36658320-06798500-BA64-4B77-B3CC-E10436655D98Q36704936-B481D37F-58D4-4873-BD88-01B4CB09E910Q36777247-ADF13836-553E-4C16-BF3B-1FE27E0FD4AEQ36910372-795A9613-B03C-45DF-AAE0-FD3AB94107F7Q36925154-A606713C-4280-4F10-BBBF-8C236979B2E0Q36965127-D6DDCB93-30A8-4C8F-A89A-0CBF67A2D00FQ37045900-6C346309-CA80-4BD5-819B-B40AFBA1A19DQ37081473-56133559-40E8-4083-904C-49F6998F610DQ37172003-1C3F5F17-C027-4751-B2D3-2AC71C00E734Q37172007-E4E842AE-7CCB-4636-B165-9AC621808140Q37357864-7A1426C0-83DF-4EDD-9D8F-75402B285AD2Q37821496-E11CAAAA-5854-4F6A-BC49-61F945102CECQ38010146-54128348-E442-4553-88C5-0AD66365957FQ38109553-737F79B3-2825-4FF3-80EE-F451D4339C23Q38258148-AE2B1BBC-F9FB-4795-9837-07A6168B32C1Q38370866-28FAC36A-C64F-4805-BD87-86F60B6F769FQ38917341-277F5E3B-0D70-46F9-B721-9B29B94B14CAQ39037933-9F0813D3-AA22-4383-8A84-A7481B090504Q39932145-2A9DA696-B92F-4B31-B351-BE6FE0B0197CQ39981858-C4B43CA3-6B12-492D-9BB7-93639E1B382F
P2860
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Diagnostic performance of quan ...... n assays in clinical practice.
@ast
Diagnostic performance of quan ...... n assays in clinical practice.
@en
Diagnostic performance of quan ...... n assays in clinical practice.
@nl
type
label
Diagnostic performance of quan ...... n assays in clinical practice.
@ast
Diagnostic performance of quan ...... n assays in clinical practice.
@en
Diagnostic performance of quan ...... n assays in clinical practice.
@nl
prefLabel
Diagnostic performance of quan ...... n assays in clinical practice.
@ast
Diagnostic performance of quan ...... n assays in clinical practice.
@en
Diagnostic performance of quan ...... n assays in clinical practice.
@nl
P2093
P1433
P1476
Diagnostic performance of quan ...... n assays in clinical practice.
@en
P2093
Jerry A Katzmann
John A Lust
Roshini S Abraham
P304
P356
10.1373/CLINCHEM.2004.046870
P407
P577
2005-03-17T00:00:00Z